Endoscopic vascular targeted photodynamic therapy with the photosensitizer WST11 for benign prostatic hyperplasia in the preclinical dog model. (2013)

Peer-Reviewed Study · Chevalier S, Cury FL, Scarlata E, El-Zayat E, Hamel L, Rocha J, Zouanat FZ, Moussa S, Scherz A, Elhilali M, Anidjar M · May 13, 2013

Chevalier S et al., 2013-05-13: Preclinical dog study of endourethral WST11 (TOOKAD Soluble) vascular-targeted PDT for benign prostatic hyperplasia, 34 dogs, 753 nm diode laser. The only BPH photodynamic study located, and it does not use methylene blue.

An optical laser fiber was positioned in the prostatic urethra of 34 dogs, including 4 controls.

Chevalier S et al., 2013-05-13: Preclinical dog study of endourethral WST11 (TOOKAD Soluble) vascular-targeted PDT for benign prostatic hyperplasia, 34 dogs, 753 nm diode laser. The only BPH photodynamic study located, and it does not use methylene blue. C3 (also C5). Study type: animal (dog), preclinical. N: 34 dogs (4 controls). Country: Canada (McGill University Health Centre group). Drug: WST11 5-15 mg/kg IV, continuous or bolus; light 753 nm, 200 mW/cm, 200-300 J, endourethral fibre. Funder: non-US government/other support per PublicationType; no GrantList captured. Conflicts: none declared. Comparator: untreated controls plus dose/route arms. Not methylene blue. Study type: animal.